Cardiology
Conference Coverage
Trial data suggest beneficial class effects of SGLT2 inhibitors, including dapagliflozin
ORLANDO – Data from EXSCEL placebo group subjects show beneficial class effects of SGLT2 inhibitors, including dapagliflozin, on MACE, ACM, and...
Conference Coverage
CVD-REAL 2: Lower mortality, CV risks with SGLT-2i vs. DPP-4i treatment in T2DM
ORLANDO – SGLT2 inhibitor treatment, compared with DPP-4 inhibitors, is associated with lower death, CV event, and stroke rates in patients with...
From the Journals
AGA Clinical Practice Update: Statins are safe, effective, and important for most patients with liver disease and dyslipidemia
With a few exceptions, patients with liver disease should receive lipid-lowering agents at full dose.
Audio
DOACs found safer than warfarin in the real world
A wearable ECG boosts atrial fibrillation detection, and more in this week’s MDedge Cardiocast.
From the Journals
New hypertension guidelines would add 15.6 million new diagnoses
A new analysis estimates that adopting the 2017 ACC/AHA hypertension guidelines would add 15 million Americans to the ranks of the hypertensives,...
Latest News
Older black patients die sooner after in-hospital cardiac arrest
Patient and hospital treatment factors accounted for less than a third of the difference.
From the Journals
Obesity triples post-MI sudden cardiac death risk
The obesity paradox makes a showing in the risk of all-cause death.
Latest News
USPSTF: Insufficient evidence for ABI screening in asymptomatic adults
Evidence is lacking even in high-risk patients.
Latest News
Alteplase, aspirin provide similar functional outcomes after nondisabling stroke
From the Journals
Patch-based AF screening boosts diagnosis rate
From the Journals
mSToPS breaks ground as a ‘pragmatic’ randomized trial